AbbVie’s Tavapadon Shines in Phase 3 Trials for Parkinson’s Disease AbbVie’s investigational drug Tavapadon has achieved positive results in the Phase 3 TEMPO-2 trial, a critical milestone in developing new therapies for Parkinson’s disease. Designed as a flexible-dos...

www.linkedin.com/pulse/abbvie...

AbbVie’s Tavapadon Shines in Phase 3 Trials for Parkinson’s Disease

#ParkinsonsDisease #Tavapadon #AbbVie #NeurologicalDisorders #DopamineReceptors #Phase3Trials #ClinicalResearch #MotorSymptomRelief #Humanteconomy #Humantec